






The **INDICAID[™] COVID-19 Rapid Antigen Test** is a point-of-care kit designed for the detection of SARS-CoV-2 antigens in direct nasal swab samples.

The test is intended for use by healthcare professionals in symptomatic individuals within 5 days after onset of symptoms.



Clinical Performance

In a prospective US clinical study, **INDICAID™** accurately identified 84% of those who were positive (PPA) and 97% of those who were negative (NPA) for SARS-CoV-2.

Product performance against variants of concern are evaluated on an ongoing basis.

1.888.932.4788 | sales@weair.ca | weairmedical.com



TECHNICAL BRIEF:

Detection of SARS-CoV-2 Genomic Variants with the INDICAID[™] COVID-19 Rapid Antigen Test

The World Health Organization (WHO) has identified genetic variants of concern of SARS-CoV-2 for which there is evidence of increased transmissibility, more severe disease, significant reduction in neutralization by antibodies, reduced effectiveness of treatments or vaccines, or diagnostic detection failures. It is important that current SARS-CoV-2 diagnostic tests remain capable of detecting these emerging variants. This technical brief describes our ongoing evaluation into the performance of INDICAID[™] COVID-19 Rapid Antigen Test with emerging SARS-CoV-2 variants.

Summary of Recombinant Nucleoprotein Testing Results

Recombinant SARS-CoV-2 nucleocapsid proteins (from Acro Biosystems, Delaware, USA) with mutations associated with individual SARS-CoV-2 variants of concern were diluted to an initial target concentration, and then tested on the INDICAID COVID-19 Rapid Antigen Test. Afterward, serial dilutions of each recombinant protein were also tested on the INDICAID COVID-19 test. Based on the results, the detection capability of the INDICAID COVID-19 Rapid Antigen Test is described below in Table 1.

WHO	IO Recombinant N Protein		
Variants SARS-CoV-2	PANGO Lineage	Mutations	Test Performance
Alpha	B.1.1.7	D3L, R203K, G204R, S235F	Not affected
Beta	B.1.351	T205I	Not affected
Gamma	P.1	P80R	Not affected
DELTA	B.1.617.2	D63G, R203M, D377Y, R385K	Not Affected
Delta Plus	AY.1 and AY.2	D63G, R203M, G215C, D377Y	Not affected

Table 1. Recombinant proteins of SARS-CoV-2 Variants of Concern and INDICAID Test Performance



Summary of B.1.617.2 Variant Clinical Specimen Testing Results

In a separate study, 25 clinical remnant nasal specimens containing the B.1.617.2 (Delta) variant in viral transport media (from Orange County Public Health Laboratory) were tested with the INDICAID COVID-19 Rapid Antigen Test. The presence of SARS-CoV-2 was determined by RT-PCR with the Perkin Elmer nCoV Nucleic Acid Detection Kit. Whole genome sequencing was then conducted on an Illumina MiSeq, using the ARTIC v.3 protocol and Nextera DNA Flex Library Prep. The INDICAID Test detected 100% (25/25) of the B.1.617.2 specimens.

visit us at us.phasescientific.com

PHASESCIENTIFIC



1.888.932.4788 | sales@weair.ca | weairmedical.com



QUICKREFERENCEGUIDE

Quick Reference Guide

INDICAID

INDICAID™ COVID-19 Rapid Antigen Test For Emergency Use Authorization (EUA) Only

Intended Use

The INDICAID™ COVID-19 Rapid Antigen Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provided within the first five (5) days of symptom onset. Anterior has swab specimers may be called by healthcare provider (HCP) or self-called (by individuals 18 years of age or older, under the supervision of an HCP). Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments three of the Clinical Laboratory improvement Amendments three of the Clinical Laboratory three three endorses of the clinical three of the clinical the clinical three of the c of 1988 (CLIA), 42 U.S.C. §263a, thatmeet the requirements to perform moderate complexity, high complexity, or waived tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waver, Certificate of Compliance, or Certificate of Accreditation.

The INDICAID[™] COVID-19 Rapid Antigen Test does not differentiate betweenSARS-CoV and SARS-CoV-2 viruses.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal swabs during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine history and other alagnostic information is necessary to determine infection status. Positive results do not rule outbacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United Statesand its territories are required to report all positive results to the appropriate public health authorities.

Negative results should be treated as presumptive and may be Negative results should be treated as presumptive and may be confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.Negative results should be considered in the cortext of a patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19.

The INDICAID™ COVID-19 Rapid Antigen Test is intended for use by Trained clinical laboratory personnel and medical and healthcare personnel in Point of Care (POC) settings. The INDICAID™ COVID-19 Rapid Antigen Test is only for use under the Food and Drug Administration's Emergency Use Authorization.

Materials required but not provided

Positive result:

1.Timer

Interpretation of the test results

2.Personal protective equipment 3.INDICAID™COVID-19 Antigen Quality Control (Sold Separately)

Materials provided in kit 1. 25 individually wrapped Test Devices 2, 25 Buffer Solution Vials 3. 25 individually wrapped Swabs 4. 11FU and Quick Reference Guide

See Package Insert for complete instruction, warnings,

- precautions, limitations, storage &handling conditions, and Quality Control recommendations.
- For in vitro diagnostic use only.
- Specimens should be tested immediately after specimen collection. Do not test specimens after 2 hours of collection.
 All components in this test kit should remain sealed until ready for
- · All components in this test kit are for one-time use only. Do not
- reuse Store at 2-30°C.Do not freeze. Avoid direct sunlight.
 If Buffer Solution comes into contact with eyes and/or skin, flush abundantly with water.
- Do not use the test kit after the expiration date

Test Procedure

Wear appropriate personal protective equipment and gloves when handling patient samples and running the test. Nasal swab specimens may be self-collected by the patient if collection procedure observed by ahealthcare professional.

- Remove the Swab & Test 01 Devicefrom their packaging. Place the Test Device on ahorizontal (flat) surface forrunning the test.
- 02 Insert the entire collection tip of the swab provided (usually $\frac{1}{2}$ to $\frac{3}{4}$ of an inch, or 1 to 1.5 cm) inside the nostril.

Firmly sample the nasal wall by rotating the swab in a arcular path against the nasal wall **at least 4 times**. Take approximately 15 seconds to collect the specimen. Be sure to collect any nasal drainage that may be present on the swab. swab

Repeat in the other nostril using the same swab.

INDICAID" COVID-19 Rapid Antigen Quality Control Kit is available separately from PHASE Scientific International, Ltd. We recommend that these external positive and negative controls are run once with every new kit lot, new shipment, and each new user

- External Control Test Procedure: Remove a new Swab & Test Device from their packaging. Place the Test Device on a horizontal (flat)
- surface for running the test.
- 2. Hold the external positive control vial vertically and remove the entire cap.
- 3. Dip the Swab into the vial, making sure that the Swab head is fully submerged in solution. Remove the Swabfrom the vial.
- 4. Test the Swab by performing Steps 3 through 7 of the Test Procedure in this Quick Reference Guid
- 5. Repeat to test the external negative control.

Control line (C)

PHATESON

8


Os

Test line (T)

Disclaimers: In the USA, this product has not beenFDA cleared or In the USA, this product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §2630, that meet requirements to perform moderate complexity, high complexity, or waived tests. This product is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under aCLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-COV-2, not for any other viruses or pathogens. In the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 under Section (364(B)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declarationis terminated or the §360bbb-3(b)(1), unless the declaration is terminated or the authorization is revoked sooner

Manufactured By

PHASE Scientific International Limited 32 & 33F, Gravity, 29 Hing Yip St., Kwun Tong, Kowloon, Hona Kona



\triangle	Caution, Consult accompanying documents		
210 - 30°C	Temperature Limitation		
$\sum_{i=1}^{n}$	Sufficient for Use		
漆	Keep away from sunlight		
Ť	Keep away from moisture		
2	Do not reuse		
Ĩ	Consult Instructions for Use		
IVD	In-Vitro Diagnostic Medical Device		
REF	Catalog number		
LOT	B atch code		
\geq	Use by		
••••	Manufacturer		
For more information, please visit			
www.phasescientific.com			
If you have questions, please contact Customer Service			
<u>Indicaid@phasesci.com</u> US +1 (657) 296-6106			
00 . 100/ 2/0 000			

P1-2110400QS |IC04QS2021 |R ev A |March2021Edition | For in-vitro diagnostic use |© PHASE Scientific Int'l Ltd., all rights



1.888.932.4788 | sales@weair.ca | weairmedical.com

Negative result:

The presence of red-colored control line (C) and no visible test line (T) indicates a negative result. No SARS-CoV-2 antigen was detected.

The presence of both the red-colored

control line (C) and colored test line (T)

indicates the presence of SARS-CoV-2 antigen. The result suggests current SARS-CoV-2 infection. Samples with low

levels of antigen may produce a faint test line. Any visible test is considered positive.

Invalid result:

If the red-colored control line (C) is not visible, DO NOT interpret the test result. The result is invalid regardless of the appearance of the test line. Collect a new nasal swab sample and repeat the assay with a new INDICAID[™] COVID-19 Rapid Antigen Test.

